Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Rishu Agarwal(Peter MacCallum Cancer Centre), Sarah‐Jane Dawson(The University of Melbourne), Dane Vassiliadis(The University of Melbourne), Paul Yeh(The Royal Melbourne Hospital), Omer Gilan(The University of Melbourne), Charis E. Teh(The University of Melbourne), Adrian Zordan(Cancer Australia), Tane Hunter(The University of Melbourne), Kathleen C. Rayeroux(Cancer Australia), Andrew W. Roberts(The Royal Melbourne Hospital), Constantine S. Tam(The Alfred Hospital), David C.S. Huang(Indonesia International Institute for Life Sciences), Sarah Ftouni(Peter MacCallum Cancer Centre), Enid Y.N. Lam(The University of Melbourne), Piers Blombery(The University of Melbourne), Stephen Q. Wong(Peter MacCallum Cancer Centre), Mark A. Dawson(The University of Melbourne), Meaghan Wall(St Vincent's Hospital Melbourne), Daniel H.D. Gray(The University of Melbourne), John F. Seymour(The Royal Melbourne Hospital), Charles C. Bell(The University of Melbourne), Mary Ann Anderson(The Royal Melbourne Hospital), Rachel Thijssen(The University of Melbourne), Jason Li(Queen's University), Kathy Knezevic(Peter MacCallum Cancer Centre), Christiane Pott(University Hospital Schleswig-Holstein), Yih-Chih Chan(The University of Melbourne)
Cited by 204
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k